RainSure Scientific key facts
as of Oct 2026- Developer and manufacturer of digital polymerase chain reaction (PCR) instruments designed for tumors.
- RainSure Scientific is valued at approximately $125.0M as of Oct 2026 (last reported valuation).
- It has raised $24.4M; the latest was Later Stage VC in Dec 2024.
- Notable investors include ZhenFund, YuanBio Venture Capital, Future Capital Discovery Fund, Zero2IPO Venture Capital, China-Singapore Suzhou Industrial Park Development Investment — 10 tracked in total.
- Status: Privately Held (backing).
RainSure Scientific's last reported valuation, Dec 2019. Nothing priced has surfaced since.
- ·Watch RainSure Scientific: the Monday email on marks, rounds and moves
RainSure Scientific funding rounds
No funding rounds for RainSure Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
RainSure Scientific valuation
RainSure Scientific's last reported valuation was $125 million in Dec 2019. No priced round, secondary trade or fund mark has surfaced since.
RainSure Scientific investors
10 investors are on record for RainSure Scientific, including ZhenFund, YuanBio Venture Capital, Future Capital Discovery Fund and Zero2IPO Venture Capital.
About RainSure Scientific
Developer and manufacturer of digital polymerase chain reaction (PCR) instruments designed for tumors. The company's platform specializing in technology innovations in microfluidics, engineering, and molecular biology, incorporates microfluidics, optics, precision instruments, electronic engineering, and biochemical technology into their digital PCR instruments, enabling patients to receive early-stage diagnosis of tumors and other diseases and received the treatment they need.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Employees
- 60
- Website
- rainsurebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.